Research Analysts Issue Forecasts for IPSC Q3 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at William Blair issued their Q3 2026 EPS estimates for shares of Century Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst S. Corwin anticipates that the company will earn ($0.47) per share for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share.

A number of other brokerages also recently commented on IPSC. Piper Sandler decreased their target price on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday. Guggenheim lowered their price objective on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics presently has an average rating of “Buy” and a consensus price target of $5.80.

Century Therapeutics Price Performance

Shares of IPSC opened at $0.56 on Friday. The stock has a market capitalization of $47.19 million, a PE ratio of -0.30 and a beta of 1.75. The business’s fifty day moving average price is $0.74 and its 200 day moving average price is $1.16. Century Therapeutics has a 12-month low of $0.52 and a 12-month high of $4.50.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds have recently bought and sold shares of IPSC. Casdin Capital LLC grew its position in Century Therapeutics by 61.6% during the fourth quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock valued at $5,242,000 after purchasing an additional 1,978,190 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after acquiring an additional 1,466,415 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Century Therapeutics by 146.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock worth $1,215,000 after acquiring an additional 714,685 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Century Therapeutics by 890.7% during the fourth quarter. Deutsche Bank AG now owns 193,368 shares of the company’s stock worth $195,000 after acquiring an additional 173,849 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Century Therapeutics during the third quarter valued at $284,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.